Mitigating Failure in Medical Device Manufacturing

Medical device failures often appear suddenly: a reported adverse event, a warning letter, or a recall. But the conditions that enable failure are rarely sudden. They are typically established much earlier, through small disconnects that accumulate across the product lifecycle: decisions made in isolation, assumptions that were never formally governed, and changes whose impact was not fully understood beyond a single team.

Despite rigorous regulatory and quality system requirements enforced by authorities such as the U.S. Food and Drug Administration (FDA) and the European medical device regulatory framework (including EU directives, regulations, and harmonized ISO standards), medical device failures continue to occur. Regulatory compliance is essential, but it does not guarantee product success or resilience in the field.

This blog highlights a few real-world examples for each of the above categories, presents viable reasons for failure, and lays out possible remedies through better governance, collaboration, and data gathering throughout the product lifecycle. These remedies will help prevent future breakdowns by applying product lifecycle management (PLM) technologies and solutions across the ideation, design, and manufacturing phases of a product’s lifecycle.

Understanding why medical devices fail requires looking beyond the failure event itself. It demands a lifecycle perspective – examining how decisions, data, and intent are created, handed off, and preserved from concept and design through verification and validation, manufacturing transfer, and post-market surveillance. Where continuity breaks down, risk takes root long before a problem is ever observed in use.

Medical device failure risk emerges when early assumptions remain informal

During early product development, organizations define patient needs, clinical use cases, and intended use. These inputs form the foundation for design inputs, risk management activities, and downstream documentation. Risk often emerges when early assumptions remain informal or insufficiently governed.

In practice, however, documentation and labeling activities are sometimes initiated later in the lifecycle or managed by teams that were not directly involved in early concept or design decisions. When access to design rationale, risk analysis, or verification evidence is limited, downstream documentation can lack critical context.

Under schedule pressure, documentation may be finalized late, translated under compressed timelines, or updated reactively rather than as part of a continuously governed product record. When this occurs, important clinical, regulatory, or usability assumptions may influence the product without being fully preserved or traceable.

When development accelerates, downstream teams inherit conclusions without context and are forced to reconstruct intent later.

When medical device design intent fractures during development

As medical device development progresses, specialization increases. Mechanical, electrical, software, quality, and regulatory teams work in parallel, often using different tools and representations of the product.

When requirements, risks, design data, and documentation are managed in disconnected systems, maintaining traceability becomes difficult. Changes may be evaluated locally rather than in full lifecycle context. A requirement change may not automatically prompt updates to risk controls, test coverage, or labeling. Over time, traceability becomes manual, fragile, and difficult to sustain.

The challenge is not a lack of expertise, but the ability to preserve design intent and decision context as products evolve.

Proving medical device compliance without preserving knowledge

Verification and validation activities confirm that a device meets its requirements and is safe and effective. Test plans are executed, results are documented, and evidence is assembled for regulatory review.

While these activities are rigorous, test artifacts are often managed as discrete deliverables rather than as connected knowledge assets. The rationale behind test coverage, the linkage to specific risk controls, and insights gained during execution are not always easy to reuse when product variants are introduced or post-market issues arise.

As a result, teams may repeat testing or struggle to respond quickly to regulatory or field inquiries—not due to a lack of data, but to a lack of accessible context.

When intent is lost on the factory floor

Design transfer is where engineering intent becomes physical reality. It is also one of the most fragile lifecycle transitions.

Engineering defines the product through an Engineering Bill of Materials (EBOM). Manufacturing builds it using a Manufacturing Bill of Materials (MBOM), work instructions, and supplier processes. When these structures are not aligned, interpretation replaces intent.

During design, the EBOM is created to represent the engineering definition of the product, including functional groupings, assemblies, and parts. Manufacturing, in turn, relies on the MBOM to define how the product is built and assembled.

In many organizations, the EBOM and MBOM are managed in different systems, often across PLM and ERP environments. While this separation reflects organizational and operational realities, it also introduces risk when changes are not synchronized or design intent is not clearly communicated.

Small discrepancies accumulate, tolerances shift, materials change, processes vary. That leads to quality erosion rather than immediate failure.

Maintaining alignment between EBOM and MBOM and ensuring that changes propagate with full context are critical to reducing medical device manufacturing errors, rework, and downstream quality issues.

When approved changes create hidden medical device failure risk

Change is constant. It could be design updates, supplier substitutions, software releases, and regional regulatory differences.

Most organizations control change formally. Yet many failures stem from changes that were approved without full lifecycle visibility.

An engineering change may not be considered a regulatory filing. A software update may overlook system-level risk. A material substitution may address a supply issue but introduce new quality concerns.

Feedback without learning

Post-market surveillance provides critical insight into real-world device performance through complaints, service data, adverse events, and corrective and preventive actions (CAPAs).

When effectively governed, PMS serves as a learning mechanism that informs medical device risk management, design improvements, and future product development. However, when post-market data remains siloed from design and engineering teams, lessons learned may not be systematically applied across product generations.

In these cases, issues may be corrected locally without addressing underlying systemic causes.

Designing medical devices for resilience requires the digital thread

Medical device failure cannot be prevented by adding more checklists or enforcing isolated controls. The growing complexity of modern medical devices demands a digital thread—an approach in which decisions, data, and design intent remain connected as products evolve.

When organizations maintain a governed, end-to-end view of the product, early assumptions remain visible, changes are evaluated in full context, manufacturing stays aligned with design, and post-market insights actively inform improvement rather than repeating past mistakes. The digital thread does not eliminate failure entirely, but it significantly reduces avoidable risk.

By connecting data, people, and processes into a single, traceable product record, digital thread solutions can mitigate medical device failure more effectively, respond faster to change, and deliver higher-quality products to market. To support this kind of lifecycle continuity and reduce the risk of medical device failure, manufacturers increasingly rely on a connected PLM platform that preserves design intent, traceability, and decision context across the entire product lifecycle. The result is not only improved compliance and efficiency, but more resilient devices – and better outcomes for the patients who rely on them.

Learn more about PLM solutions for the Medical Device industry here.